Zafgen, Inc. (ZFGN)

Home » Stocks » ZFGN

May 29, 2020 - ZFGN merged into LRMR

Stock Price: $0.990 USD 0.000 (0.00%)

Updated May 28, 2020 4:00 PM EDT

• Overview
• News
• Financials

Key Info

Market Cap	37.10M
Revenue (ttm)	n/a
Net Income (ttm)	n/a
Shares Out	37.47M
EPS (ttm)	-0.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Dividend Yield	n/a

Stock Quote

Trading Day	May 28, 2020
Last Price	$0.990
Previous Close	$0.990
Change ($)	0.000
Change (%)	0.00%
Day's Open	1.020
Day's Range	10.000 - 12.510
Day's Volume	4,323,149
52-Week Range	0.619 - 12.510

More Stats

Market Cap	37.10M
Enterprise Value	n/a
Earnings Date (est)	n/a
Ex-Dividend Date	n/a
Shares Outstanding	37.47M
Float	28.46M
EPS (basic)	-0.97
EPS (diluted)	-0.96
FCF / Share	-0.92

Dividend	n/a
Dividend Yield	n/a
Earnings Yield	n/a
FCF Yield	n/a
Payout Ratio	n/a
Shares Short	523,135
Short Ratio	2.48
Short % of Float	1.84%
Beta	0.27

PE Ratio	n/a
Forward PE	n/a
P/FCF Ratio	n/a
PS Ratio	n/a
PB Ratio	0.73
Revenue	n/a
Operating Income	-35.94M
Net Income	n/a
Free Cash Flow	-34.27M

Net Cash	44.45M
Net Cash / Share	1.19
Gross Margin	n/a
Operating Margin	n/a
Profit Margin	n/a
FCF Margin	n/a
ROA	-20.65%
ROE	-53.93%
ROIC	-56.90%

Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy	0
Overweight	0
Hold	0
Underweight	0
Sell	0

What these ratings mean

Analyst Consensus: n/a

Price Target

$9.36*

Low

9.36

Current: $0.990

High

9.36

Target: 9.36

*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Income Statement | Balance Sheet | Cash Flow

Year	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	-	-	-	-	-	-	-	-
Operating Income	-45.65	-61.12	-53.00	-58.23	-73.81	-35.53	-13.78	-13.79
Net Income	-45.41	-61.37	-52.03	-57.88	-74.29	-36.48	-14.03	-13.88
Shares Outstanding	37.35	32.23	27.43	27.30	26.76	12.19	0.73	0.71
Earnings Per Share	-1.22	-1.90	-1.90	-2.12	-2.78	-3.00	-19.53	-19.65
Operating Cash Flow	-40.78	-51.49	-43.78	-51.98	-59.55	-28.24	-15.00	-13.59
Capital Expenditures	-1.35	-0.11	-0.06	-0.66	-0.60	-0.06	-0.02	-
Free Cash Flow	-42.13	-51.60	-43.84	-52.64	-60.15	-28.30	-15.02	-13.59
Cash & Equivalents	71.60	118	102	129	185	115	35.52	-
Total Debt	22.58	20.64	20.00	3.59	6.39	7.56	-	-
Net Cash / Debt	49.02	97.43	82.05	126	179	108	35.52	-
Assets	80.73	122	106	132	189	118	38.14	-
Liabilities	27.11	28.49	27.29	9.89	20.00	13.08	2.92	-
Book Value	53.62	93.27	78.22	122	169	104	-68.57	-

Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name	Zafgen, Inc.
Country	United States
Employees	7
CEO	Jeffrey S. Hatfield

Stock Information

Ticker Symbol	ZFGN
Stock Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology
Unique Identifier	NASDAQ: ZFGN
IPO Date	June 19, 2014

Description

Zafgen is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA.